论文部分内容阅读
目的探讨抗HPV生物蛋白辅料治疗宫颈高危型HPV16、18型感染的临床实用性。方法收集2015年1月-2016年1月来在北华大学附属医院确诊为慢性宫颈炎同时伴有高危型HPV16、18型感染的患者60例,随机分为两组,对照组(保妇康栓组30例)和治疗组(抗HPV生物蛋白辅料组30例),两组均进行HPV16、18型检查。结果用药后3个月及6个月治疗组HPV转阴率及有效率明显升高,与对照组比较有统计学差异(P<0.05)。结论抗HPV生物蛋白辅料治疗宫颈高危型HPV16、18型感染临床疗效显著,能降低宫颈癌的发生。
Objective To investigate the clinical utility of anti-HPV bio-protein adjuvant in the treatment of cervical high-risk HPV type 16 and 18 infections. Methods Sixty patients with chronic cervicitis and high-risk HPV16 and 18 infections diagnosed at Beihua University Affiliated Hospital from January 2015 to January 2016 were randomly divided into two groups. The control group (Baofukang 30 in the suppository group) and the treatment group (30 in the anti-HPV bio-protein adjuvant group). HPV16 and 18 were examined in both groups. Results After 3 months and 6 months after treatment, the negative rate and effective rate of HPV in treatment group were significantly higher than those in control group (P <0.05). Conclusion The anti-HPV bio-protein adjuvant is effective in treating cervical high-risk HPV type 16 and 18 infection and can reduce the occurrence of cervical cancer.